Introduction：Basic information about CAS 203849-91-6|MMAD, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | MMAD |
|---|
| CAS Number | 203849-91-6 | Molecular Weight | 771.064 |
|---|
| Density | 1.1±0.1 g/cm3 | Boiling Point | 906.1±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C41H66N6O6S | Melting Point | / |
|---|
| MSDS | / | Flash Point | 501.8±34.3 °C |
|---|
Names
| Name | Monomethylauristatin D |
|---|
| Synonym | More Synonyms |
|---|
MMAD BiologicalActivity
| Description | MMAD is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugates (ADCs). |
|---|
| Related Catalog | Signaling Pathways >>Antibody-drug Conjugate >>ADC CytotoxinSignaling Pathways >>Cell Cycle/DNA Damage >>Microtubule/TubulinSignaling Pathways >>Cytoskeleton >>Microtubule/TubulinResearch Areas >>Cancer |
|---|
| Target | Tubulin[1] |
|---|
| In Vitro | MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity[1]. |
|---|
| In Vivo | The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats[1]. |
|---|
| References | [1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9. |
|---|
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|
| Boiling Point | 906.1±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C41H66N6O6S |
|---|
| Molecular Weight | 771.064 |
|---|
| Flash Point | 501.8±34.3 °C |
|---|
| Exact Mass | 770.476440 |
|---|
| LogP | 5.82 |
|---|
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
|---|
| Index of Refraction | 1.537 |
|---|
| InChIKey | BLUGYPPOFIHFJS-UUFHNPECSA-N |
|---|
| SMILES | CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(Cc1ccccc1)c1nccs1)OC)N(C)C(=O)C(NC(=O)C(NC)C(C)C)C(C)C |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| N-Methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]-1-pyrrolidinyl}-5-methyl-1-oxo-4-heptanyl]-N-methyl-L-valinamide |
| L-Valinamide, N-methyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- |
| MFCD25976743 |
| Demethyldolastatin 10 |
| Monomethylauristatin D |
| Monomethyl Dolastatin 10 |
| MMAD |
